Medications

Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...

Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.

People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...

Many patients and clinicians seek safer, non-immunosuppressive options for Crohn’s disease. This randomized trial found LDN did not induce endoscopic or clinical remission, though it may reduce fatigue—information that...

This study provides real‑world data on how long biologic‑experienced UC patients stay on ustekinumab, which helps patients and clinicians set expectations about drug persistence and factors that might influence stopping...

For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...

Patients who lose response to standard upadacitinib dosing may have a practical option—dose re‑escalation—that could improve symptoms and reduce steroid needs according to a small retrospective cohort summarized here.

Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.

People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...

Long-term, real-world safety data help patients and clinicians understand risks — especially serious infections — when a newer ulcerative colitis drug is used in routine practice. This registry entry shows Pfizer is...

This study builds a large, public single-cell map of the gut in Crohn’s disease that identifies cell types and gene programs linked to inflammation. That can help researchers find new drug targets and explain why some...

A new IL-17A drug (vunakizumab) is reported to have triggered severe ulcerative colitis in one patient, suggesting clinicians and patients starting IL-17A inhibitors should watch for early gastrointestinal symptoms.

This real-world multicenter study provides short-term effectiveness and safety data for upadacitinib in a difficult-to-treat Crohn’s population in China, which may inform treatment decisions and risk discussions.

The findings suggest that early biologic and immunomodulator treatment may reduce the need for first surgery in Crohn's disease, which is directly relevant to treatment planning and expectations for people with IBD.

Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.

Based on the title and source metadata, this appears to be a regulatory update related to Medications. The original article is from firstwordpharma.com.

The findings show earlier and more frequent use of imaging, endoscopic assessment, anti-TNF therapy, and seton placement for active perianal fistulizing Crohn’s disease over recent years — practices that may affect...

This is the official FDA drug label for dexamethasone sodium phosphate. It names ulcerative colitis and regional enteritis (Crohn’s disease) among indications where systemic corticosteroids can be used, so it’s relevant...

This FDA drug-label update describes approved uses and safety warnings for tofacitinib, a JAK inhibitor used in immune-mediated diseases including ulcerative colitis. The boxed warnings highlight serious infection and...

The study suggests that anti‑TNF treatment in IBD is associated with weaker and less cross‑reactive antibody and memory B‑cell responses after COVID‑19 booster vaccination, which may reduce durability of protection and...

This is the official FDA label text for dexamethasone, so it clarifies approved uses and gives practical dosing and tapering guidance. It explicitly names "regional enteritis and ulcerative colitis," which matters to...

This label update confirms current FDA prescribing information for sulfasalazine delayed‑release tablets, which many people with ulcerative colitis may be prescribed for induction and maintenance of remission.

Label updates list safety warnings and monitoring steps that can affect people taking APRISO (mesalamine) for ulcerative colitis. Knowing these helps patients and clinicians watch for serious side effects and manage...

This FDA label page documents official prescribing information for SOLU-CORTEF (hydrocortisone), including explicit gastrointestinal/IBD indications (regional enteritis and ulcerative colitis) and IV/IM dosing guidance.

Herpes zoster is more common and can be more severe in people with IBD, especially those on certain immunosuppressive drugs. Understanding therapy-specific risks and vaccine options can help prevent painful...

Medication adherence affects how well IBD maintenance treatment works. This study highlights the everyday challenges and beliefs that shape whether people stick with prescribed therapies, which can help clinicians and...

Iliopsoas abscess is an uncommon but serious penetrating complication of Crohn’s disease that can present with non-specific symptoms and be missed. The review compiles case-level evidence about presentation, diagnosis,...

If you or your clinician are using upadacitinib for Crohn’s, intestinal ultrasound early in treatment may help predict who will not respond and who is more likely to relapse on maintenance dosing, potentially guiding...

The study suggests that in some people with IBD who have Candida overgrowth, systemic antifungal therapy (fluconazole) can change gut microbes and metabolites in ways linked to better disease activity over 8 weeks. That...

This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...

This gives families and clinicians a non‑TNF biologic option on‑label for children aged 2+ with moderate‑to‑severe ulcerative colitis, which can change insurance conversations and expand treatment choices for kids who...

This study maps cell types in newly diagnosed pediatric Crohn's and links diagnostic cell patterns to disease severity and anti‑TNF treatment response. That could help predict which children are likely to benefit from...

Proactive monitoring of adalimumab levels could help keep drug concentrations therapeutic and reduce loss of response during maintenance therapy for ulcerative colitis.

Label changes for RENFLEXIS affect people with Crohn's disease or ulcerative colitis who take (or may be prescribed) infliximab biosimilars — the label includes dosing, age indications, and important safety warnings that...

Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.

This study maps cell-level signatures in newly diagnosed pediatric Crohn’s and links them to later severity and responses to anti-TNF treatment, which could help predict which children will respond to biologic therapy...

This matters because many patients and clinics face procurement-driven switches from reference biologics to biosimilars; early evidence here suggests short-term outcomes and treatment persistence are similar after...

The FDA approval expands an approved biologic option (ustekinumab/Stelara) to children aged two and older with moderately to severely active ulcerative colitis, giving families and clinicians another treatment choice. It...

The study suggests a steroid‑sparing combination (low‑dose atorvastatin plus reduced prednisolone) may produce stronger anti‑inflammatory and antioxidant effects than either drug alone in an animal model of ulcerative...

This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.

This registry entry describes a completed Phase 2 study of a new IV drug (tulisokibart) for moderate–severe ulcerative colitis, including safety endpoints and a companion diagnostic — information patients may want when...

This trial tests a novel cell-derived extracellular vesicle therapy (DB-3Q) for people with Crohn’s disease who have not responded to standard advanced therapies. It may offer a different biologic approach if proven safe...

This study looks at how immunomodulators are actually used with biologic drugs in real-world practice when a national reimbursement policy forces biologic interruptions.

If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...

The study outlines a strategy to target corticosteroids to inflamed intestinal tissue by exploiting PLA2 overexpression, which could reduce systemic steroid side effects if the approach translates to biological models...

This review directly compares surgery-first versus biologic-first strategies for localized ileocaecal Crohn's disease and suggests early resection can lower later treatment needs and leave some patients off medication,...

Cure8 found this source from marketwatch.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...